HealthNewsAPI
A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China - CNBC
Overview
An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a closely watched late-stage trial in China. The benefit was reported when the drug was given in combination with another therapy. This result could influence investor and regulatory sentiment after recent high-profile rejections and adds to broader signs of progress across different cancer-treatment approaches.
Entities
ORGCNBCORGAkesoORGSummit TherapeuticsLOCChina
Relationship Graph
Click a connection line between nodes to view confidence and evidence.
Nodes: 3 · Connections: 2
Caused by
Led to
Related to
Same event
Press enter or space to select a node. You can then use the arrow keys to move the node around. Press delete to remove it and escape to cancel.
Press enter or space to select an edge. You can then press delete to remove it or escape to cancel.
Click a connection for evidence · click a node to open it
Select a connection to see why these events are linked.